Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

L2 Diagnostics LLC (AKA: L-Two Diagnostics LLC)
Profile last edited on: 2/10/2020      CAGE: 43BA5      UEI: GKA7VH5LFR25

Business Identifier: Candidate biomarkers in diagnosis of Lyme disease, ETBF, and diabetes.
Year Founded
1998
First Award
1999
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

300 George Street Unit 309
New Haven, CT 06511
   (203) 494-5288
   l2dx@aol.com
   www.l2dx.com
Location: Single
Congr. District: 03
County: New Haven

Public Profile

L2 Diagnostics is a private biotechnology firm spinoff from The Yale School of Medicine Lyme/Lupus Diagnostics Laboratory. L2 Diagnostics is developing new diagnostic methods that will help distinguish patients infected with Lyme disease from those who have been vaccinated. The firm has broadened its scope of R&D into disease biomarkers and therapies. The firm is identified as working to develop diagnostics and therapeutics and to be located Department of Internal Medicine, Yale School of Medicine

Extent of SBIR involvement

User Avatar
Phase I Awards
59
Phase II Awards
32
Conversion Rate
54.24%
Phase I Dollars
$14,885,515
Phase II Dollars
$24,284,245
Total Awarded
$39,169,760

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $2,562,068
Project Title: A Novel Vaccine Against Mosquito-Borne Zika Virus Based on Mosquito Salivary Gland Protein AGBR1
2022 2 NIH $599,028
Project Title: A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1
2022 2 NIH $2,376,221
Project Title: An Antigen-Detection Assay to Diagnose Babesia Microti Infection
2021 2 NIH $593,086
Project Title: Vaccination against Zika virus infection using mosquito NeSt1 protein
2020 2 NIH $592,338
Project Title: Immunization with Mosquito Agtrio Protein to Prevent Malaria

Key People / Management

  Martin J Mattessich -- President

  Karen G Anthony

  Linda Bockenstedt

  Nathalie Marie Bonafe

  Michael Cappello

  Erol Fikrig

  Kevan C Herold

  Raymond Morris Johnson

  Barbara I Kazmierczak

  Raymond A Koski

  Michel E Ledizet

  Mark J Mamula

  Yorgo Modis

  Saraspadee Mootien

  Saraspadee Mootien

  Sukanya Narasimhan

  Elizabeth Peterson-Roth

  Diane Mcmahon Pratt

  Elizabeth P Roth

  Alan Sutherland

  Sahar Usmani-Brown

  Sahar Usmanibrown

  Narendra Wajapeyee

  Jason Weinstein

  Adam Wisnewski

Company News

Nov 23 2012
Reports from L2 Diagnostics Describe Recent Advances in Staphylococcus aureus